Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects

Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis

(2016) Y Xu et al.   CTS-Clinical and Translational Science

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis

(2016) Lucy Platt et al.   LANCET INFECTIOUS DISEASES

Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy

(2015) Enju Liu et al.   AIDS

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

(2014) Matt S Anderson et al.   ANTIVIRAL THERAPY

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

(2014) Josep M Gatell et al.   Journal of the International AIDS Society

Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission

(2014) Luis M. Agosto et al.   PLoS Pathogens

Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine

(2013) Beth Williamson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

(2013) Iris Usach et al.   Journal of the International AIDS Society

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

(2012) M. Sharma et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study

(2011) B. Hasse et al.   CLINICAL INFECTIOUS DISEASES

Etravirine, a Next‐Generation Nonnucleoside Reverse‐Transcriptase Inhbitor

(2009) Leonard B. Johnson et al.   CLINICAL INFECTIOUS DISEASES